AKO004 / Core One Labs - LARVOL DELTA

Core One Labs’ Akome Seeks to Revolutionize Treatment of Parkinson’s Disease and Submits Application to Protect IP (GlobeNewswire) - "Core One Labs...announce that its wholly owned subsidiary Akome Biotech Ltd. ('Akome') has commenced the development of another breakthrough psychedelic drug formulation, and confirms the filing of another provisional patent application with the United States Patent and Trademark Office (USPTO) under application number 63147338, for the protection of its intellectual property designed to address Parkinson’s Disease, also known as AKO004."

Patent • CNS Disorders • Parkinson's Disease